Abstract:BACKGROUND:The etiology and pathomechanism of schizophrenia are unknown. The traditional dopamine (DA) hypothesis is unable to fully explain its pathology and therapeutics. The glutamate (Glu) and γ-aminobutyric acid (GABA) hypotheses suggest Glu or GABA concentrations are abnormal in the brains of patients with schizophrenia. Magnetic resonance spectroscopy (MRS) show glutamate level increases in the ventromedial prefrontal cortex (vmPFC) including the anterior cingulated cortex (ACC) in those with schizophrenia.AIMS:To investigate the function of the glutamate system (glutamate and γ-aminobutyric acid) in the etiology and pathomechanism of schizophrenia.METHODS:24 drug naïve patients with schizophrenia and 24 healthy volunteers were matched by gender, age, and educational level. The Siemens 3T MRI system was used to collect the magnetic resonance spectroscopy (MRS) data of the subjects. The regions of interest included the left dorsolateral prefrontal cortex (IDLPFC), ventromedial prefrontal cortex (vmPFC), and anterior cingulate cortex (ACC). LCModel software was used to analyze the concentrations of γ-aminobutyric acid (GABA), glutamate (Glu), glutamine (Gln), N-acetylaspartate (NAA), and N-acetylaspartylglutamate (NAAG) in the region of interest. Meanwhile, the Positive and Negative Syndrome Scale (PANSS) and the Clinical Global Impression Scale (CGI) were used to assess the mental symptoms and severity of the disease.RESULTS:The median GABA concentrations in the anterior cingulate cortex of the schizophrenia group and the healthy control group were 1.90 (Q1=1.55, Q3=2.09) and 2.16 (Q1=1.87, Q3=2.59) respectively; the mean (sd) Glu concentrations were 6.07 (2.48) and 6.54 (1.99); the median Gln concentrations were 0.36 (Q1=0.00, Q3=0.74) and 0.29 (Q1=0.00, Q3=0.59); the between-group difference of the GABA concentrations was statistically significant (Z=-2.95, p=0.003); the between-group difference of the GABA/(NAA+NAAG) was statistically significant (Z=-2.72, p=0.012); the between-group difference of Glu and Gln was not statistically significant. The age of the schizophrenia group was negatively correlated with the GABA concentration in the anterior cingulate (R=-0.494, p=0.014), and negatively correlated with GABA/ (NAA+NAAG) (R=-0.473, p=0.020). Yet there was no such correlation in the control group. After calibration, no significant correlation was found between the clinical symptoms and the concentrations of the metabolites.CONCLUSIONS:The concentration of glutamate in the vemtromedial prefrontal cortex of patients with schizophrenia was abnormal, whereas the concentration of GABA in the anterior cingulate cortex decreased, supporting the hypothesis of abnormal glutamate -GABA in the brains of those individuals with schizophrenia. In patients with schizophrenia, the GABA in the anterior cingulate cortex had an accelerated decline with age. The clinical symptoms may be correlated to the metabolite concentration of the anterior cingulate cortex.

Reduced Γ-Aminobutyric Acid and Glutamate+Glutamine Levels in Drug-Naïve Patients with First-Episode Schizophrenia but Not in Those at Ultrahigh Risk

Neuronal Dysfunction in Individuals at Early Stage of Schizophrenia, A Resting-State Fmri Study

Multiomics Analyses Reveal Microbiome–Gut–Brain Crosstalk Centered on Aberrant Gamma-Aminobutyric Acid and Tryptophan Metabolism in Drug-Naïve Patients with First-Episode Schizophrenia

Anterior Cingulate Cortex Glutamate Levels Are Related to Response to Initial Antipsychotic Treatment in Drug-Naive First-Episode Schizophrenia Patients

Alteration of the Gut Microbiome in First-Episode Drug-Naïve and Chronic Medicated Schizophrenia Correlate with Regional Brain Volumes.

Epigenetic Clock Analysis of Blood Samples in Drug-Naive First-Episode Schizophrenia Patients.

Altered Effective Connectivity in the Default Network of the Brains of First-Episode, Drug-Naïve Schizophrenia Patients with Auditory Verbal Hallucinations

Relationships Between Dorsolateral Prefrontal Cortex Metabolic Change and Cognitive Impairment in First-Episode Neuroleptic-Naive Schizophrenia Patients.

Associations Between Cognitive Function and Levels of Glutamatergic Metabolites and Gamma-Aminobutyric Acid in Antipsychotic-Naïve Patients With Schizophrenia or Psychosis

Prolonged Cortical Silent Period among Drug-Naive Subjects at Ultra-High Risk of Psychosis.

Abnormal Concentration of GABA and Glutamate in the Prefrontal Cortex in Schizophrenia.-An in Vivo 1H-MRS Study.

Comparison of the Density of Gamma-Aminobutyric Acid in the Ventromedial Prefrontal Cortex of Patients with First-Episode Psychosis and Healthy Controls.

Neurochemical and Brain Functional Changes in the Ventromedial Prefrontal Cortex of First-Episode Psychosis Patients: A Combined Functional Magnetic Resonance Imaging-Proton Magnetic Resonance Spectroscopy Study.

N-acetylaspartate reduction in the medial prefrontal cortex following 8 weeks of risperidone treatment in first-episode drug-naïve schizophrenia patients.

Longitudinal follow-up of asymmetric changes by proton magnetic resonance spectroscopy in first-episode schizophrenia patients

Short-term Effects of Antipsychotic Treatment on Cerebral Function in Drug-Naive First-Episode Schizophrenia Revealed by “resting State” Functional Magnetic Resonance Imaging

Metabolite differences in the medial prefrontal cortex in schizophrenia patients with and without persistent auditory verbal hallucinations: a 1 H MRS study

Detection of Metabolites in the White Matter of Frontal Lobes and Hippocampus with Proton in First‐episode Treatment‐naïve Schizophrenia Patients

Metabolite differences in the medial prefrontal cortex in schizophrenia patients with and without persistent auditory verbal hallucinations: a <SUP>1</SUP>H MRS study

Comparison of the density ofgamma-aminobutyric acid in the ventromedial prefrontal cortex of paitents with ifrst-episode psychosis and healthy controls

Higher-order functional brain networks and anterior cingulate glutamate + glutamine (Glx) in antipsychotic-naïve first episode psychosis patients